Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Boehringer Third-Generation Lung Cancer Drug Deemed 'Breakthrough' Therapy

This article was originally published in Scrip

Executive Summary

Boehringer Ingelheim won a breakthrough therapy designation from the US FDA for its lung cancer drug candidate BI 1482694 (HM61713), a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that the German firm licensed from Hanmi Pharmaceutical Co. Ltd. in July, which will face stiff competition from several other EGFR-targeting therapies.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register